CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pfenex Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pfenex Inc
10790 Roselle Street
Phone: (858) 352-4400p:858 352-4400 San Diego, CA  92121  United States Fax: (858) 352-4602f:858 352-4602

This company was Merged or Acquired on 10/1/2020.
This company ceased filing statements with the SEC on 10/5/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board JasonGrenfell-Gardner 45 12/31/2018 1/1/2017
Chief Executive Officer, President, Secretary and acting Principal Financial Officer and Principal Evert B.Schimmelpennink 48 11/13/2019 8/3/2017
Chief Operating Officer, Senior Vice President Shawn A.Scranton 56 10/1/2018 10/1/2018
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Pfçnex Inc.
Pfenex Limited
PFNX
reagentproteins.com

General Information
Number of Employees: 88 (As of 6/30/2020)
Outstanding Shares: 34,296,593 (As of 8/5/2020)
Shareholders: 20
Stock Exchange: AMEX
Federal Tax Id: 271356759
Fax Number: (858) 352-4602
Email Address: proteins@pfenex.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023